Nuntius Therapeutics

📍 London, United Kingdom🗓 Founded 2021👥 12 employees💰 Last funded Apr 2021
Biotechnology Research🌐 nuntiustx.com
Website LinkedIn
We overcome the biggest challenge for genetic medicines: Safe and effective delivery. We developed a field-leading proprietary technology for systemic nucleic acid delivery, based on scalable non-immunogenic materials. Our patented data-driven high-throughput screening platform allows us to screen novel nanocarrier formulations at unparalleled scale. We use our cell-specific nanocarriers to develop mRNA and gene editing therapies for currently incurable diseases. Our pipeline includes immunotherapies, which we strive to advance rapidly into the clinic.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Nuntius Therapeutics?
Nuntius Therapeutics has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Nuntius Therapeutics last raise funding?
The most recent investment in Nuntius Therapeutics recorded on gritt.io was in April 2021.
When was Nuntius Therapeutics founded?
Nuntius Therapeutics was founded in 2021.
What industry is Nuntius Therapeutics in?
Nuntius Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Nuntius Therapeutics based?
Nuntius Therapeutics is headquartered in London, United Kingdom.